Diffuse glioma overview based on the 2021 WHO classifi cation part 2 – pediatric type

Download PDF Česká verzia

Authors: M. Hendrych ¹; M. Barák ²; H. Valeková ²; T. Kazda ³; P. Pospíšil ³; R. Lakomý ⁴; J. Šána ^4,5; R. Jančálek ²; M. Hermanová ¹
Authors place of work: I. ústav patologie, LF MU a FN u sv. Anny v Brně ¹; Neurochirurgická klinika LF MU a FN U sv. Anny v Brně ²; Klinika radiační onkologie LF MU a MOÚ, Brno ³; Klinika komplexní onkologické péče LF MU a MOÚ, Brno ⁴; CEITECH – Středoevropský technologický institut, MU, Brno ⁵
Published in the journal: Cesk Slov Neurol N 2024; 87(1): 9-17
Category: Review Article
doi: https://doi.org/10.48095/cccsnn20249

Summary

The fifth edition of the WHO Classification of Tumors of the Central Nervous System categorizes diffuse gliomas into the pediatric type, which mainly affects children, and into the adult type of diffuse gliomas occurring dominantly in adult patients. Recently characterized tumors, defined for the first time according to the 2021 WHO classification, have been included in the group of diffuse gliomas of the pediatric type. At the same time, established gliomas have undergone changes in their diagnostic criteria, reflecting the latest insights from molecular-genetic research. This second part of the review presents a comprehensive summary of tumors classified into the pediatric-type diffuse gliomas group according to the fifth edition of the WHO Classification of Tumors of the Central Nervous System published in 2021.

Keywords:

diffuse glioma – WHO CNS 2021 – integrated diagnostics – PLNTY – angiocentric glioma – diffuse astrocytoma – diffuse midline glioma – diffuse hemispheric glioma – low-grade glioma – high-grade glioma

Zdroje

1. Louis DN, Perry A, Wesseling P et al. The 2021 WHO classification of tumors of the central nervous system: a summary. Neuro Oncol 2021; 23 (8): 1231–1251. doi: 10.1093/neuonc/noab106.

2. WHO Classification of Tumours Editorial Board. World Health Organization Classification of Tumours of the Central Nervous System. Lyon: International Agency for Research on Cancer 2021.

3. Toll SA, Tran HN, Cotter J et al. Sustained response of three pediatric BRAFV600E mutated high-grade gliomas to combined BRAF and MEK inhibitor therapy. Oncotarget 2019; 10 (4): 551–557. doi: 10.18632/oncotarget.26560.

4. Nicolaides T, Nazemi KJ, Crawford J et al. Phase I study of vemurafenib in children with recurrent or progressive BRAFV600E mutant brain tumors: Pacific Pediatric Neuro-Oncology Consortium study (PNOC-002). Oncotarget 2020; 11 (21): 1942–1952. doi: 10.18632/oncotarget.27600.

5. Jackson ER, Persson ML, Fish CJ et al. A review of the anti-tumor potential of current therapeutics targeting the mitochondrial protease ClpP in H3K27-altered, diffuse midline glioma. Neuro Oncol 2023; noad144. doi: 10.1093/neuonc/noad144.

6. Laetsch TW, DuBois SG, Mascarenhas L et al. Larotrectinib for paediatric solid tumours harbouring NTRK gene fusions: phase 1 results from a multicentre, open-label, phase 1/2 study. Lancet Oncol 2018; 19 (5): 705–714. doi: 10.1016/S1470-2045 (18) 30119-0.

7. Manoharan N, Liu KX, Mueller S et al. Pediatric low-grade glioma: targeted therapeutics and clinical trials in the molecular era. Neoplasia 2023; 36: 100857. doi: 10.1016/j.neo.2022.100857.

8. Krueger DA, Care MM, Holland K et al. Everolimus for subependymal giant-cell astrocytomas in tuberous sclerosis. N Engl J Med 2010; 363 (19): 1801–1811. doi: 10.1056/NEJMoa1001671.

9. Bouffet E, Hansford JR, Garrè ML et al. Dabrafenib plus trametinib in pediatric glioma with BRAF V600 mutations. N Engl J Med 2023; 389 (12): 1108–1120. doi: 10.1056/NEJMoa2303815.

10. Ellison DW, Hawkins C, Jones DTW et al. cIMPACT-NOW update 4: diffuse gliomas characterized by MYB, MYBL1, or FGFR1 alterations or BRAF V600E mutation. Acta Neuropathol 2019; 137 (4): 683–687. doi: 10.1007/s00401-019-01987-0.

11. Ryall S, Zapotocky M, Fukuoka K et al. Integrated molecular and clinical analysis of 1,000 pediatric low- -grade gliomas. Cancer Cell 2020; 37 (4): 569–583.e5. doi: 10.1016/j.ccell.2020.03.011.

12. Wefers AK, Stichel D, Schrimpf D et al. Isomorphic diffuse glioma is a morphologically and molecularly distinct tumour entity with recurrent gene fusions of MYBL1 or MYB and a benign disease course. Acta Neuropathol 2020; 139 (1): 193–209. doi: 10.1007/s00401-019-02078-w.

13. Blümcke I, Luyken C, Urbach H et al. An isomorphic subtype of long-term epilepsy-associated astrocytomas associated with benign prognosis. Acta Neuropathol 2004; 107 (5): 381–388. doi: 10.1007/s00401-004-0833-3.

14. Chiang J, Harreld JH, Tinkle CL et al. A single-center study of the clinicopathologic correlates of gliomas with a MYB or MYBL1 alteration. Acta Neuropathol 2019; 138 (6): 1091–1092. doi: 10.1007/s00401-019-02081-1.

15. Ampie L, Choy W, Didomenico JD et al. Clinical attributes and surgical outcomes of angiocentric gliomas. J Clin Neurosci 2016; 28: 117–122. doi: 10.1016/ j.jocn.2015.11.015.

16. Bandopadhayay P, Ramkissoon LA, Jain P et al. MYB-QKI rearrangements in angiocentric glioma drive tumorigenicity through a tripartite mechanism. Nat Genet 2016; 48 (3): 273–282. doi: 10.1038/ng.3500.

17. Lellouch-Tubiana A, Boddaert N, Bourgeois M et al. Angiocentric neuroepithelial tumor (ANET): a new epilepsy-related clinicopathological entity with distinctive MRI. Brain Pathology 2005; 15 (4): 281–286. doi: 10.1111/j.1750-3639.2005.tb00112.x.

18. Huse JT, Snuderl M, Jones DTW et al. Polymorphous low-grade neuroepithelial tumor of the young (PLNTY): an epileptogenic neoplasm with oligodendroglioma-like components, aberrant CD34 expression, and genetic alterations involving the MAP kinase pathway. Acta Neuropathol 2017; 133 (3): 417–429. doi: 10.1007/s00401-016-1639-9.

19. Johnson DR, Giannini C, Jenkins RB et al. Plenty of calcification: imaging characterization of polymorphous low-grade neuroepithelial tumor of the young. Neuroradiology 2019; 61 (11): 1327–1332. doi: 10.1007/s00234-019-02269-y.

20. Gupta VR, Giller C, Kolhe R et al. Polymorphous low-grade neuroepithelial tumor of the young: a case report with genomic findings. World Neurosurg 2019; 132: 347–355. doi: 10.1016/j.wneu.2019.08.221.

21. Blümcke I, Coras R, Busch RM et al. Toward a better definition of focal cortical dysplasia: an iterative histopathological and genetic agreement trial. Epilepsia 2021; 62 (6): 1416–1428. doi: 10.1111/epi.16899.

22. Hendrych M, Hemza J, Kočvarová J et al. Polymorphous low-grade neuroepithelial tumor of the young. Cesk Slov Neurol N 2021; 84/117 (3): 282–285. doi: 10.48095/cccsnn2021282.

23. Bale TA, Sait SF, Benhamida J et al. Malignant transformation of a polymorphous low grade neuroepithelial tumor of the young (PLNTY). Acta Neuropathol 2021; 141 (1): 123–125. doi: 10.1007/s00401-020-02245-4.

24. Zhang J, Wu G, Miller CP et al. Whole-genome sequencing identifies genetic alterations in pediatric low-grade gliomas. Nat Genet 2013; 45 (6): 602–612. doi: 10.1038/ng.2611.

25. Qaddoumi I, Orisme W, Wen J et al. Genetic alterations in uncommon low-grade neuroepithelial tumors: BRAF, FGFR1, and MYB mutations occur at high frequency and align with morphology. Acta Neuropathol 2016; 131 (6): 833–845. doi: 10.1007/s00401-016-1539-z.

26. Louis DN, Giannini C, Capper D et al. cIMPACT-NOW update 2: diagnostic clarifications for diffuse midline glioma, H3 K27M-mutant and diffuse astrocytoma/anaplastic astrocytoma, IDH-mutant. Acta Neuropathol 2018; 135 (4): 639–642. doi: 10.1007/s00401-018- 1826-y.

27. Sievers P, Sill M, Schrimpf D et al. A subset of pediatric-type thalamic gliomas share a distinct DNA methylation profile, H3K27me3 loss and frequent alteration of EGFR. Neuro Oncol 2021; 23 (1): 34–43. doi: 10.1093/neuonc/noaa251.

28. Castel D, Kergrohen T, Tauziède-Espariat A et al. Histone H3 wild-type DIPG/DMG overexpressing EZHIP extend the spectrum diffuse midline gliomas with PRC2 inhibition beyond H3-K27M mutation. Acta Neuropathol 2020; 139 (6): 1109–1113. doi: 10.1007/s00401-020-02142-w.

29. Buczkowicz P, Bartels U, Bouffet E et al. Histopathological spectrum of paediatric diffuse intrinsic pontine glioma: diagnostic and therapeutic implications. Acta Neuropathol 2014; 128 (4): 573–581. doi: 10.1007/s00401-014-1319-6.

30. Solomon DA, Wood MD, Tihan T et al. Diffuse midline gliomas with histone H3-K27M mutation: a series of 47 cases assessing the spectrum of morphologic variation and associated genetic alterations. Brain Pathology 2016; 26 (5): 569–580. doi: 10.1111/bpa. 12336.

31. Hoffman LM, Van Zanten SEMV, Colditz N et al. Clinical, radiologic, pathologic, and molecular characteristics of long-term survivors of Diffuse Intrinsic Pontine Glioma (DIPG): a collaborative report from the International and European Society for Pediatric Oncology DIPG registries. J Clin Oncol 2018; 36 (19): 1963–1972. doi: 10.1200/JCO.2017.75.9308.

32. Brat DJ, Aldape K, Bridge JA et al. Molecular biomarker testing for the diagnosis of diffuse gliomas. Arch Pathol Lab Med 2022; 146 (5): 547–574. doi: 10.5858/arpa.2021-0295-CP.

33. Habiba U, Sugino H, Yordanova R et al. Loss of H3K27 trimethylation is frequent in IDH1-R132H but not in non-canonical IDH1/2 mutated and 1p/19q codeleted oligodendroglioma: a Japanese cohort study. Acta Neuropathol Commun 2021; 9 (1): 95. doi: 10.1186/s40478-021-01194-7.

34. Filipski K, Braun Y, Zinke J et al. Lack of H3K27 trimethylation is associated with 1p/19q codeletion in diffuse gliomas. Acta Neuropathol 2019; 138 (2): 331–334. doi: 10.1007/s00401-019-02025-9.

35. Louis DN, Wesseling P, Aldape K et al. cIMPACT-NOW update 6: new entity and diagnostic principle recommendations of the cIMPACT-Utrecht meeting on future CNS tumor classification and grading. Brain Pathol 2020; 30 (4): 844–856. doi: 10.1111/bpa.12 832.

36. Crowell C, Mata-Mbemba D, Bennett J et al. Systematic review of diffuse hemispheric glioma, H3 G34-mutant: outcomes and associated clinical factors. Neurooncol Adv 2022; 4 (1): vdac133. doi: 10.1093/noajnl/vdac 133.

37. Lim KY, Won JK, Park CK et al. H3 G34-mutant high-grade glioma. Brain Tumor Pathol 2021; 38 (1): 4–13. doi: 10.1007/s10014-020-00378-8.

38. Korshunov A, Capper D, Reuss D et al. Histologically distinct neuroepithelial tumors with histone 3 G34 mutation are molecularly similar and comprise a single nosologic entity. Acta Neuropathol 2016; 131 (1): 137–146. doi: 10.1007/s00401-015-1493-1.

39. Gessi M, Gielen GH, Hammes J et al. H3.3 G34R mutations in pediatric primitive neuroectodermal tumors of central nervous system (CNS-PNET) and pediatric glioblastomas: possible diagnostic and therapeutic implications? J Neurooncol 2013; 112 (1): 67–72. doi: 10.1007/s11060-012-1040-z.

40. Trejo-Lopez JA, Praska CE, Zepeda Mendoza C et al. H3 G34 mutation assessment for diffuse gliomas in adults: when would testing be most diagnostically useful? J Neuropathol Exp Neurol 2022; 82 (1): 93–95. doi: 10.1093/jnen/nlac102.

41. Korshunov A, Schrimpf D, Ryzhova M et al. H3-/IDH-wild type pediatric glioblastoma is comprised of molecularly and prognostically distinct subtypes with associated oncogenic drivers. Acta Neuropathol 2017; 134 (3): 507–516. doi: 10.1007/s00401-017-1710-1.

42. Tauziède-Espariat A, Debily MA, Castel D et al. An integrative radiological, histopathological and molecular analysis of pediatric pontine histone-wildtype glioma with MYCN amplification (HGG-MYCN). Acta Neuropathol Commun 2019; 7 (1): 87. doi: 10.1186/s40478-019-0738-y.

43. Clarke M, Mackay A, Ismer B et al. Infant high-grade gliomas comprise multiple subgroups characterized by novel targetable gene fusions and favorable outcomes. Cancer Discov 2020; 10 (7): 942–963. doi: 10.1158/2159-8290.CD-19-1030.

44. Guerreiro Stucklin AS, Ryall S, Fukuoka K et al. Alterations in ALK/ROS1/NTRK/MET drive a group of infantile hemispheric gliomas. Nat Commun 2019; 10 (1): 4343. doi: 10.1038/s41467-019-12187-5.